Migalastat Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Migalastat Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
26
Registered trials
20
Result records
6
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Migalastat Hydrochloride can convert its Small molecule drug profile and GALA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Migalastat Hydrochloride (query alias: migalastat) |
|---|---|
| Modality / target | Small molecule drug; GALA; GLA stimulants |
| Highest global status | Approved |
| Originator | Amicus Therapeutics, Inc. |
| Active developers | Amicus Therapeutics, Inc., Amicus Therapeutics Europe Ltd., Amicus Therapeutics Pty Ltd. |
The MCP disease footprint includes Fabry Disease, Kidney Failure, Chronic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04049760 | Phase 3 | Completed | 16 | Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug |
| NCT06904261 | Phase 3 | Recruiting | 8 | Safety: Incidence of TEAEs, SAEs, and AEs leading to discontinuation of study drug |
| NCT06906367 | Not Applicable | Recruiting | 450 | Annualized rate of change in Estimated Glomerular Filtration Rate (eGFR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants
Phase 3; n=16; evaluation: not stated. Reported fields: -; -; Number of subjects with TEAEs = 13 Participants
WCN24-2159 REAL-WORLD EVIDENCE REGARDING RENAL EFFECT OF MIGALASTAT
Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: GFR = 85 mL/min/1.73m2 ( 75 - 95)
FollowME Fabry Pathfinders registry: baseline characteristics of patients with 3-year migalastat treatment
Not Applicable; n=427; evaluation: not stated. Reported fields: -; Acroparasthesia = 33.3 % ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Migalastat Hydrochloride addresses Fabry Disease, Kidney Failure, Chronic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-12-19 | BioMarin Completes Acquisition of Amicus Therapeutics | Approved | US$4,800.0M stated total |
| 2022-01-11 | Amicus Therapeutics and Genpharm Services Sign Distribution Agreement for the Treatment of Amenable Patients Living with Fabry Disease | Approved | Financial terms not disclosed |
| 2019-03-05 | Handok Signs Distributorship Agreement with Amicus Therapeutics to Sell Galafold® – the World’s First Oral Treatment for Fabry Disease – in Korea | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Capsule formulations comprising migalastat”. The milestone feed surfaced a patent-application signal described as “Methods of improving the pharmacokinetics of migalastat”. The milestone feed surfaced a patent-application signal described as “Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
